Immunexpress Secures New EU Patent for Immune Biomarkers for Herpes Virus Infection

April 1, 2013 – Today, Immunexpress Group announced the granting of one of its core biomarker patents, “microarray-mediated diagnosis of herpes virus infection by monitoring host’s differential gene expression upon treatment” in the European Union (EU). This patent compliments the U.S. herpes virus patent secured by the Company in late 2012.

These patents cover host response molecules and assays for the diagnosis of the herpes virus as well as for the detection of specific immune responses to an infection or the reactivation of the herpes virus, which can occur in sepsis patients and may contribute to increases in sepsis severity.

Published scientific literature now supports the notion that reactivation of latent viruses such as cytomegalovirus (CMV) and other herpes viruses in critically ill patients can increase severity of sepsis, lengthen the stay of patients in Intensive Care Units (ICU) and hospital, as well as increase patient mortality rates. As part of its research strategy, Immunexpress is exploring novel biomarker panels of the patient’s immune response to identify the reactivation of viruses, such as herpes, in the absence of clinical signs; this early detection may enable better treatment and management decisions for sepsis patients and immuno-compromised patients at risk of sepsis.


Read more about the U.S. patent here.